Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated
improved clinical outcomes over chemotherapy alone in patients with previously untreated …

Background Pembrolizumab improved survival as first-and second-line therapy compared
with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing …

Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC) …

Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …

Pembrolizumab monotherapy has become the preferred treatment for patients with
advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 …

Background The anti-programmed death 1 monoclonal antibody pembrolizumab has shown
antitumour activity and is a first-line and second-line treatment option for patients with …

Introduction: Immune checkpoint inhibitors targeting programmed death protein 1 (PD-1)
receptor and its ligand, PD-L1, have recently led to significant and durable improvements in …

Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab
significantly improved progression-free survival and overall survival (OS) compared with …

Background Single-agent pembrolizumab represents the standard first-line option for
metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …